Gitnux/Report 2026

Fertility Industry Statistics

Fertility care is being reshaped by fresh 2026 numbers, including faster clinic cycle times, shifting success rates, and changing demand across age and treatment types. Read how these trends collide in the same dataset, revealing what patients may experience now and what clinics are preparing for next.
262Statistics
74Sources
12Sections
1Visuals
45mRead
November 11, 2026Updated
Fertility Industry Statistics
Henrik DahlWritten by Henrik Dahl·Edited by Thomas Lindqvist·Fact-checked by Sarah Mitchell
Published ·Updated
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The fertility industry at a glance

The fertility industry is expanding as infertility affects 17.5% of adults globally, while U.S. clinics performed 435,426 ART cycles in 2022 and fertility-services revenue is forecast to reach $70.3 billion by 2030.

$52.7B[58]
Global market size, 2026
7.5%[58]
Forecast CAGR, 2024–2030
435,426[37]
U.S. ART cycles, 2022
1.15M+[59]
European ART cycles, 2023
Market size
The global fertility-services market was valued at $42.2 billion in 2023 and is projected to reach $52.7 billion in 2026. The estimate covers fertility diagnosis, treatment and preservation services.[58]
Forecast & CAGR
The global market is forecast to grow at a 7.5% compound annual growth rate from 2024 through 2030, reaching $70.3 billion by 2030. Growth is attributed to wider IVF adoption, rising infertility prevalence and greater availability of fertility-preservation services.[58]
Market share & regions
Europe reported more than 1.15 million medically assisted reproduction cycles in 2023, making it one of the largest documented regional treatment markets. In the United States, 457 clinics reported ART activity in 2022, with 98,289 live-born infants resulting from treatment.[59][37]
Segmentation
Fertility services are commonly segmented into diagnosis, treatment and preservation. In the U.S. ART system, 184,423 of the 435,426 cycles reported in 2022 were egg- or embryo-banking cycles, while the broader treatment mix includes IVF, intracytoplasmic sperm injection and frozen-embryo transfer.[58][37][59]
Key players & concentration
The market remains fragmented across fertility clinics, laboratory networks, donor and cryobank providers, pharmaceutical companies and fertility-benefits administrators. Progyny reported 6.7 million covered members and 555 clients at December 31, 2025, illustrating the scale of a leading benefits platform rather than concentration of the entire clinical market.[11]
Pricing
A U.S. IVF cycle commonly costs $15,000–$30,000 when clinic procedures, medications and embryo genetic testing are included. A 2026 actuarial analysis estimated average total IVF costs of $29,585 per patient among commercially insured members in fully mandated states.[60][61]
Trends, drivers & challenges
Infertility affects an estimated 17.5% of adults globally, or about one in six people, creating substantial unmet demand. Key growth drivers include delayed childbearing, expanding fertility preservation and employer benefits, while high out-of-pocket costs, unequal insurance coverage and limited access remain major constraints.[62][11]
Consumer behavior & competition
Demand is shifting toward fertility preservation, frozen-embryo transfer and employer-sponsored benefits. Progyny reported 65,006 ART cycles among members in 2025 and a 1.32% annual utilization rate across an average 6.719 million members, while European data show frozen-embryo transfer delivery rates of 27.6% per transfer versus 24.4% for IVF and 23.5% for ICSI.[11][59]
M&A
Industry consolidation continued in 2026. INVO Fertility completed its acquisition of Family Beginnings, a fertility clinic serving Indiana and the broader Midwest, on February 19, 2026; strategic activity also extended into fertility therapeutics, with Gedeon Richter acquiring Celmatix’s women’s-health discovery portfolio in March 2026.[11][63]
Regulation
In the United States, the Fertility Clinic Success Rate and Certification Act of 1992 requires ART clinics to report annual procedure and outcome data to the CDC. Embryology laboratories may be accredited through the College of American Pathologists or The Joint Commission, and CDC reporting requirements were most recently modified in an August 2024 Federal Register notice.[37]
Latest news
Recent developments include the February 2026 completion of INVO Fertility’s Family Beginnings acquisition and Gedeon Richter’s March 2026 acquisition of Celmatix’s fertility-related discovery assets, including an oral FSH-receptor agonist candidate intended to simplify ovarian stimulation.[11][63]

02 Ranking

Top 10 Companies in the Fertility Industry

The leading companies in the fertility industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 11, 2026 · Next review December 11, 2026

Verdict

Ferring Pharmaceuticals leads Gitnux's 2026 fertility ranking with an Overall score of 9.2, with assisted-reproduction technology medicines in assisted reproduction pharmaceuticals. FutureLife is the highest-ranked fertility clinic operator at 9.1, with 61 clinics spanning 15 European countries in fertility clinics and reproductive genetics.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in fertility pharmaceuticals

    Ferring Pharmaceuticals

    CH

    Ranked #1 · 9.2 · Fertility pharmaceuticals

    Why we picked it: Its assisted-reproduction technology medicines sit within fertility pharmaceuticals and assisted reproduction medicines.

    See in ranking ↓Visit ferring.com ↗

  2. Leader in fertility clinics

    FutureLife

    CZ

    Ranked #2 · 9.1 · Fertility clinics

    Why we picked it: Its footprint in fertility clinics and reproductive genetics covers multiple countries through 61 clinics.

    See in ranking ↓Visit futurelifegroup.com ↗

  3. Leader in assisted-reproduction devices

    The Cooper Companies

    US

    Ranked #5 · 8.9 · Assisted-reproduction devices

    Why we picked it: Its fertility and women's-health activity is tied to revenue growth of 5% and 17% operating margin.

    See in ranking ↓Visit coopercos.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the fertility industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Ferring Pharmaceuticals

Fertility pharmaceuticals · CH

9.2
2

FutureLife

Fertility clinics · CZ

9.1
3

IVIRMA Global

Fertility clinics · ES

9.1
4

Merck KGaA

Fertility pharmaceuticals · DE

8.9
5

The Cooper Companies

Assisted-reproduction devices · US

8.9
6

CARE Fertility

UK, Ireland, Spain and US fertility clinics · GB

8.7
7

Genea

Australian fertility clinics and IVF laboratory technology · AU

8.4
8

Monash IVF Group

Australian and Southeast Asian fertility clinics · AU

8.0
9

Organon

Fertility pharmaceuticals and women's health · US

7.9
10

Indira IVF

India fertility clinics and IVF services · IN

7.8

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 11, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Henrik Dahl. (2026, February 13). Top 10 companies in the fertility industry. In Fertility Industry Statistics. Gitnux. https://gitnux.org/fertility-industry-statistics/#top-companies

report visual · Projection

Number of ART embryo transfer cycles (United States)

Number of ART embryo transfer cycles grew from 157K in 2017 to 206K in 2022.

157.5K count
Start
+5.55%
CAGR · 5y
206.3K count
Projected
20172022
source-verifiedcdc.gov2022

04 Statistics

Technology & Innovation

AI and digital tooling is most common in embryology laboratories: 74.9% of surveyed fertility clinics reported use in 2024, while 48.3% flagged system integration as a challenge.

AI in the fertility industry

  • 64.1% of surveyed fertility clinics reported using AI or digital technology for administrative activities in 2024 across participating international clinics.[1]
  • 53.1% of surveyed fertility clinics cited better data management as a benefit of AI or digital technology in 2024 across participating international clinics.[1]
  • 40.7% of surveyed fertility clinics reported using AI or digital technology during ovarian stimulation in 2024 across participating international clinics.[1]
  • 48.3% of surveyed fertility clinics identified integration with existing systems as an AI-adoption challenge in 2024 across participating international clinics.[1]
  • 74.9% of surveyed fertility clinics reported using AI or digital technology in embryology laboratories in 2024 across participating international clinics.[1]
  • 1,066 IVF patients were enrolled across 14 fertility clinics in Australia and Europe in a 2024 randomized trial of deep-learning embryo selection.[2]

Automation in the fertility industry

  • 11 IVF patients underwent treatment using three serially connected automated laboratory systems in Mexico between April and October 2024.[3]
  • 3 automated systems were connected in sequence for sperm preparation, oocyte retrieval and denudation, sperm selection, laser immobilization, and piezo-ICSI in a 2024 Mexican clinical deployment.[3]
  • 4 major automation domains were identified for IVF laboratories in a 2026 review: AI-assisted embryo selection, semi-automated vitrification, robotic ICSI, and end-to-end laboratory automation.[4]

Digital Transformation in the healthcare services sector (sector benchmark)

  • Across U.S. non-federal acute care hospitals, 71% used predictive AI integrated into electronic health records in 2024.[5]
  • About 70% of surveyed healthcare executives said investing in technology platforms for digital tools and services would be important or very important in 2025.[6]
  • Among healthcare respondents to KPMG’s global technology survey, 49% were adopting DevSecOps approaches to adapt digital-transformation strategies.[7]
  • About 90% of surveyed global healthcare C-suite executives expected digital technology use to accelerate in 2025, including 50% anticipating a significant impact.[6]
  • Across surveyed healthcare practitioners, 60% believed their organizations’ digital experiences met or exceeded customer needs in 2025.[8]

Technology Adoption in the healthcare services sector (sector benchmark)

  • Across U.S. non-federal acute care hospitals, 70% enabled patient access through applications using HL7 FHIR specifications in 2024.[5]
  • Across U.S. non-federal acute care hospitals, 81% enabled patient access through applications using application-programming-interface specifications in 2024.[5]
  • Across U.S. non-federal acute care hospitals, 84% enabled patients to transmit health information to a third party electronically in 2024.[5]
  • Across U.S. non-federal acute care hospitals, 99% enabled patients to view health information electronically in 2024.[5]
  • Across U.S. non-federal acute care hospitals, 96% enabled patients to download health information electronically in 2024.[5]
  • Across U.S. non-federal acute care hospitals, 92% enabled patients to securely message providers in 2024.[5]

Cloud Computing in the healthcare services sector (sector benchmark)

  • Across surveyed healthcare organizations globally, 8% reported minimal cloud adoption without formal strategy or governance at the end of 2025.[9]
  • Across surveyed healthcare organizations globally, 27% reported that cloud operations were well managed and integrated into overall IT strategy at the end of 2025.[9]
  • Across surveyed healthcare organizations globally, 31% had a formal cloud strategy and governance framework that was not yet integrated into IT strategy at the end of 2025.[9]
  • Across surveyed healthcare organizations globally, 18% had started adopting cloud services but lacked a comprehensive cloud strategy at the end of 2025.[9]
  • Across surveyed healthcare organizations globally, 15% reported that cloud adoption was fully integrated into business strategy at the end of 2025.[9]

Big Data in the healthcare services sector (sector benchmark)

  • Across Brazilian healthcare facilities conducting Big Data analytics, 65% used patient demographics, forms, or medical-record data in 2024.[10]
  • Across Brazilian healthcare facilities conducting Big Data analytics, 38% used geolocation data from mobile phones, wireless connections, or GPS in 2024.[10]
  • Across Brazilian healthcare facilities conducting Big Data analytics, 72% used data from smart devices or sensors in 2024.[10]
  • Across Brazilian healthcare facilities conducting Big Data analytics, 48% used social-media data in 2024.[10]
  • Across Brazilian healthcare facilities conducting Big Data analytics, 77% used in-house staff rather than external providers in 2024.[10]

05 Statistics

Data & Analytics

Data quality and governance remain operational bottlenecks: 40% of U.S. clinical data abstractors reported incomplete data hampers registry efforts in 2024.

Business intelligence in the fertility industry

  • 1 business-intelligence tool using Microsoft Power BI was used by a Brazilian ART program to create competency profiles for doctors, embryologists and process stages.[3]
  • 7 operational capabilities were identified for the ART business-intelligence workflow: data consolidation, real-time monitoring, process optimization, cost analysis, benchmarking, predictive analytics and compliance reporting.[3]

Data analytics in the fertility industry

  • 6.7 million Progyny members supplied utilization data for the company’s fertility-benefits platform at December 31, 2025.[11]
  • 1.32% was Progyny’s all-member fertility-benefit utilization rate in 2025, based on average members and assisted-reproductive-treatment cycles.[11]
  • 3 reproductive-health product categories received new Basecare registrations in 2024: cryopreservation, gene sequencing and sperm-quality analysis.[12]

Data Quality in the healthcare services sector (sector benchmark)

  • 50% of U.S. healthcare clinical data abstractors reported that data inaccuracies hamper clinical registry efforts in 2024.[13]
  • 8% of U.S. healthcare organizations rated their provider data as excellent in 2022.[14]
  • 40% of U.S. healthcare clinical data abstractors reported that incomplete data hampers clinical registry efforts in 2024.[13]
  • 40% of U.S. healthcare clinical data abstractors reported that manual data entry hampers clinical registry efforts in 2024.[13]
  • 75% of U.S. healthcare organizations represented in the survey predominantly used clinical registry data for quality and process improvement in 2024.[13]

Data Governance in the healthcare services sector (sector benchmark)

  • 38% of healthcare organizations had formal data and information quality-management statements in 2025.[14]
  • 72% of healthcare organizations operated governance using approved policy and standards frameworks in 2025.[14]
  • 10% of healthcare organizations managed data governance exclusively within IT in 2025.[14]
  • 77% of healthcare organizations reported that their governance functions met at least quarterly in 2025.[14]
  • 39% of healthcare organizations reported having a formally chartered data-governance function in 2025.[14]
  • 66% of healthcare organizations reported multidisciplinary representation in governance, including patient or consumer representatives, in 2025.[14]

KPIs in the fertility industry

  • 95% of UK fertility patients providing HFEA clinic feedback in 2024/25 reported privacy and dignity during treatment.[15]
  • 93% of UK fertility patients providing HFEA clinic feedback in 2024/25 understood everything happening throughout their treatment.[15]
  • 92% of UK fertility patients providing HFEA clinic feedback in 2024/25 reported empathy and understanding from clinic staff.[15]
  • 65,006 assisted-reproductive-treatment cycles were recorded for Progyny members in 2025, a core utilization KPI for its fertility-benefits business.[11]
  • 73% of UK fertility patients were satisfied with their most recent treatment in the HFEA’s 2024 patient-experience KPI survey.[15]
  • 1.32% was Progyny’s all-member utilization rate in 2025, compared with 1.31% in 2024.[11]

06 Statistics

Strategy & Growth

Volume and coverage both move: the HFEA licensed 141 fertility clinics in 2024/25 and Progyny’s ART cycles rose to 65,006 in 2025 from 61,114 in 2024.

Growth in the fertility industry

  • The United Kingdom recorded over 100,000 fertility treatment and freezing cycles in 2024.[15]
  • Progyny served 555 clients in 2025 versus 473 in 2024.[16]
  • The HFEA licensed 141 United Kingdom fertility clinics in 2024/25, six more than in 2023/24.[15]
  • Progyny’s ART cycles increased to 65,006 in 2025 from 61,114 in 2024.[16]
  • INVO Fertility’s consolidated clinic revenue increased 4% to $6.721 million in fiscal 2025.[11]
  • Progyny’s membership grew to 6.7 million in 2025 from approximately 110,000 when its fertility-benefits solution launched in 2016.[16]

Differentiation in the fertility industry

  • INVO Fertility operated four United States fertility clinics and continued selling its INVOcell technology to third-party clinics in 2026.[11]
  • Progyny launched its fertility-benefits solution with five employer clients in 2016.[16]
  • INVO Fertility’s Family Beginnings clinic generated approximately $0.2 million in trailing twelve-month net income through September 2025.[11]
  • INVO Fertility’s Family Beginnings clinic generated approximately $1.2 million in trailing twelve-month revenue through September 2025.[11]

Mergers and acquisitions in the fertility industry

  • IVI-RMA Global’s acquisition of ART Fertility Clinics was estimated at $400 million–$450 million in 2025.[17]
  • IVI-RMA Global acquired Eugin Group’s North American operations, including Boston IVF, for $535 million in 2024.[17]
  • Private-equity investment in reproductive health involved 41 buyouts totaling $8.4 billion in 2021, according to a 2026 fertility-market analysis.[18]
  • Only three United States fertility clinics had been purchased by networks in 2025 at the time of Fertility Bridge’s year review.[19]
  • IVI-RMA Global acquired three Southern California fertility platforms—Reproductive Health and Wellness, Rise Fertility and Halo Fertility—in January 2025.[20]
  • INVO Fertility acquired Wisconsin Fertility Institute in August 2023, more than tripling its annual revenue.[11]

Strategic partnerships in the fertility industry

  • CHG Healthcare selected Progyny as its fertility, family-building and women’s-health benefits provider for more than 4,000 employees.[21]
  • Progyny’s addressable employer market represented approximately 106 million potential covered lives in 2025.[11]
  • Amazon provided Progyny fertility benefits to United States non-seasonal part-time and full-time employees from 2019 through 2024.[22]
  • Progyny had 473 employer clients representing 6.472 million members at December 31, 2024.[11]
  • Progyny’s potential employer market included approximately 9,000 United States employers with at least 1,000 employees in 2025.[11]
  • Progyny partnered with more than 650 clinics and over 1,000 providers in the United States in 2024.[23]

07 Statistics

People & Workforce

Workforce capacity is a constraint for lab throughput: 68% of surveyed IVF laboratory directors said staffing levels were insufficient for optimal workload distribution.

Hiring in the fertility industry

  • 68% of surveyed IVF laboratory directors said current staffing levels were insufficient for optimal workload distribution in a global survey cited in 2025 research.[3]
  • 72% of surveyed IVF laboratory directors reported difficulty filling open embryologist positions in a global survey cited in 2025 research.[3]
  • 80% to 81% of embryologists reported working overtime in evidence summarized by a 2026 occupational-health review.[24]

Employee retention in the fertility industry

  • 48.1% of Spanish assisted-reproduction embryologists reported low personal accomplishment in a 2024 professional survey.[25]
  • 72.1% of Spanish assisted-reproduction embryologists reported high emotional exhaustion in a 2024 professional survey.[25]
  • 48.1% of Spanish assisted-reproduction embryologists reported depersonalization in a 2024 professional survey.[25]
  • 62% of US embryologists reported high emotional exhaustion in evidence summarized by a 2026 occupational-health review.[24]
  • 59% of UK embryologists reported high emotional exhaustion in evidence summarized by a 2026 occupational-health review.[24]

Remote Work in the healthcare services sector (sector benchmark)

  • Across U.S. medical groups, 22% of leaders expected their organization’s share of remote or hybrid jobs to increase during 2024.[26]
  • Across U.S. medical groups, 18% of leaders expected their organization’s share of remote or hybrid jobs to decrease during 2024.[26]
  • Across U.S. health care and social assistance, 18% of full-time employees worked fully from home during December 2024–March 2025.[27]
  • Across U.S. medical groups, 52% reported that 1%–25% of their workforce worked remotely at least 50% of the time.[26]

Hybrid Work in the healthcare services sector (sector benchmark)

  • Across U.S. healthcare support roles, 14% had part-time remote availability, equivalent to hybrid availability, in the 2022 McKinsey American Opportunity Survey.[26]
  • Across U.S. health care and social assistance, 24% of full-time employees were in hybrid arrangements during December 2024–March 2025.[27]
  • About 6% of U.S. healthcare jobs were hybrid in a 2024 Robert Half survey cited by the Medical Group Management Association.[26]
  • Across U.S. healthcare practitioners and technical roles, 16% had part-time remote availability, equivalent to hybrid availability, in the 2022 McKinsey American Opportunity Survey.[26]
  • About 12% of nonclinical healthcare administrative and customer-support jobs were hybrid in a 2024 Robert Half survey cited by the Medical Group Management Association.[26]

Upskilling in the fertility industry

  • 24 to 36 months was the estimated time required for an embryologist to reach full competence across modern IVF procedures, compared with 12 months in 2000.[3]
  • 27.8% of UK embryologists reported stress and mental-health problems in evidence summarized by a 2026 occupational-health review, indicating a need for workforce-support training.[24]

Employee Engagement in the healthcare services sector (sector benchmark)

  • Across 2.3 million U.S. healthcare workers, employee engagement declined by 0.02 points in 2024.[28]
  • Across U.S. healthcare workers, 78% believed their organization cared about their safety in 2024.[28]
  • Among U.S. healthcare advanced practice providers, 52% felt heard in 2024.[28]
  • U.S. registered nurses with low teamwork scores were 1.53 times more likely to leave their healthcare organization in 2024.[28]
  • Across U.S. healthcare organizations, employee turnover fell from 20% to 18% in 2024.[28]

DEI in the fertility industry

  • 88% of U.S. reproductive endocrinology and infertility fellowship websites used diversity-specific language in a 2024 review.[3]
  • 100% of U.S. reproductive endocrinology and infertility fellowship websites in the high-scoring group listed DEI-related resources or opportunities in a 2024 review.[3]
  • 88% of U.S. reproductive endocrinology and infertility fellowship websites provided a dedicated DEI webpage in a 2024 review.[3]
  • 88% of U.S. reproductive endocrinology and infertility fellowship websites included a commitment-to-DEI message in a 2024 review.[3]

Change Management in the healthcare services sector (sector benchmark)

  • Among United Kingdom healthcare transformation studies, 67% reported successful transformation.[29]
  • Among Canadian healthcare transformation studies, 40% reported successful transformation and 60% reported either success or partial success.[29]

08 Statistics

Customer & Sales

Patient experience and follow-through differ by engagement channel; 41% returned to care after a follow-up email versus 32% without the email in a U.S. clinic study.

Customer experience in the fertility industry

  • 87% of UK fertility patients were satisfied that they were treated with dignity and privacy in 2024.[15]
  • 18% of UK fertility patients were dissatisfied with treatment coordination or administration in 2024.[15]
  • 73% of UK fertility patients said their personal chance of treatment success was communicated clearly in 2024.[15]
  • 50% of UK fertility patients who had not had a baby were satisfied with their treatment experience in 2024.[15]
  • 89% of UK fertility patients were satisfied with how well they understood what they were consenting to in 2024.[15]

Customer retention in the fertility industry

  • 46.56% of fertility patients returned for a repeat fresh cycle within one year after a failed complete cycle when using a smartphone application in a clinic cohort.[3]
  • 30.68% of 3,214 couples did not return after their first fertility consultation in Italy in 2021.[30]
  • 31% of responding patients in a U.S. fertility-clinic follow-up study made a follow-up appointment after receiving an email in 2018–2019.[31]
  • 41% of infertility patients who received a follow-up email returned to care, compared with 32% without the email, in a U.S. clinic study conducted in 2018–2019.[31]
  • 24.92% of couples did not return after their first fertility consultation during 2012–2021 in Italy.[30]

Customer acquisition in the fertility industry

  • 52% of UK patients in female same-sex or gender-diverse couples considered LGBTQIA+ specialization important when choosing a clinic in 2024.[15]
  • 46.2% of oncofertility patients converted from consultation to fertility-preservation treatment after Connecticut’s 2018 insurance mandate.[31]
  • 28.8% of oncofertility patients converted from initial consultation to fertility-preservation treatment before Connecticut’s 2018 insurance mandate.[31]
  • 71.4% of eligible male and female oncofertility patients pursued sperm cryopreservation after Connecticut’s 2018 insurance mandate.[31]
  • 14.3% of eligible male and female oncofertility patients pursued sperm cryopreservation before Connecticut’s 2018 insurance mandate.[31]

Lead generation in the fertility industry

  • 209% was the average search-visibility increase reported for fertility-clinic marketing campaigns in a Fuel Online case-study portfolio.[32]
  • 39% was the average cost-per-lead reduction reported for fertility-clinic marketing campaigns in a Fuel Online case-study portfolio.[32]
  • 159% was the average lead growth reported for fertility-clinic marketing campaigns in a Fuel Online case-study portfolio.[32]
  • 116% was the average pipeline increase reported for fertility-clinic marketing campaigns in a Fuel Online case-study portfolio.[32]

09 Statistics

Marketing & Brand

Online reputation varies substantially: the weighted-average Google rating across 671 fertility centers in 2026 was 4.20 stars, and 35.6% of IVF-center ratings were below four stars.

Marketing in the fertility industry

  • 58% of UK fertility patients used the HFEA website for fertility-treatment information or support in 2024.[15]
  • Nearly 70% of UK fertility patients were familiar with the HFEA in 2024.[15]
  • 62% of UK fertility patients said clinic location was the most important factor in choosing a provider in 2024.[15]
  • 50% of single UK fertility patients considered cost important when choosing a clinic in 2024, compared with 25% of opposite-sex couples.[15]
  • 47% of Black UK fertility patients considered cost important when choosing a clinic in 2024, compared with 29% of other patient groups.[15]

Digital marketing in the fertility industry

  • 159% was the average lead growth reported for fertility-clinic digital-marketing campaigns in a Fuel Online case-study portfolio.[32]
  • 116% was the average pipeline increase reported for fertility-clinic digital-marketing campaigns in a Fuel Online case-study portfolio.[32]
  • 39% was the average cost-per-lead reduction reported for fertility-clinic digital-marketing campaigns in a Fuel Online case-study portfolio.[32]
  • 222% was the average increase in AI visibility reported for fertility-clinic digital-marketing campaigns in a Fuel Online case-study portfolio.[32]

Branding in the fertility industry

  • 60 fertility practices achieved at least 4.5 stars and more than 100 reviews in a 2026 benchmark of 671 centers.[33]
  • The top 10% of fertility practices accounted for one-third of all patient reviews in a 2026 benchmark.[33]
  • 35.6% of IVF-center ratings were below four stars in a 2026 fertility reputation benchmark.[33]
  • 4.20 stars was the weighted-average Google rating across 671 fertility centers in a 2026 online-reputation benchmark.[33]
  • More than one-third of fertility practices scored below 4.0 stars in a 2026 benchmark of 671 centers.[33]

Influencer Marketing in the healthcare services sector (sector benchmark)

  • 8.57 million influencer posts about the health industry generated a 1.07% average engagement rate globally in 2023.[34]
  • 92% of U.S.-focused health and wellness influencers included product or service promotions at least occasionally in 2026.[35]
  • 50% of healthcare and pharmaceutical marketers reported dedicated, growing creator/influencer budgets in 2026, compared with 58% globally.[36]
  • 33% of U.S.-focused health and wellness influencers promoted a product, service or subscription in more than half of their posts in 2026.[35]
  • 38% of posts from U.S.-focused health and wellness influencers promoted a product, service or subscription in 2026.[35]

10 Statistics

Operations & Execution

U.S. outcomes are tracked alongside cycle mix; in 2022, 98,289 live-born infants resulted from ART cycles at U.S. clinics, including 184,423 egg- or embryo-banking cycles in which all resulting eggs or embryos were frozen.

Process optimization in the fertility industry

  • 2.6% of all U.S. infants born in 2022 resulted from ART treatment.[37]
  • 94,039 live-birth deliveries resulted from U.S. ART cycles in 2022.[37]
  • 251,542 unique patients received ART at U.S. fertility clinics in 2022.[37]
  • 206,304 embryo-transfer cycles were performed in U.S. fertility clinics in 2022.[37]
  • 98,289 live-born infants resulted from ART cycles at U.S. clinics in 2022.[37]

Operational efficiency in the fertility industry

  • 413,776 ART cycles were performed at U.S. fertility clinics in 2021.[38]
  • 112,088 clinical pregnancies resulted from U.S. ART cycles started in 2021.[38]
  • 10 months is approximately the minimum period before clinics can report complete live-birth outcomes for a reporting year.[37]
  • 453 U.S. fertility clinics reported verified ART outcomes for cycles started in 2021.[38]
  • 98% of U.S. ART cycles were estimated to be covered by CDC surveillance in 2021.[38]

Supply chain in the fertility industry

  • 184,423 U.S. ART cycles were egg or embryo banking cycles in which all resulting eggs or embryos were frozen in 2022.[37]
  • 45,779 ART banking cycles were recorded by U.S. fertility clinics in 2015.[37]
  • 103,078 ART banking cycles were recorded by U.S. fertility clinics in 2018.[37]
  • 121,086 ART banking cycles were recorded by U.S. fertility clinics in 2019.[37]
  • 123,304 ART banking cycles were recorded by U.S. fertility clinics in 2020.[37]

Outsourcing / Offshoring in the healthcare services sector (sector benchmark)

  • 20% of U.S. medical-group leaders planned to outsource or automate some revenue-cycle-management activities in 2024, according to an MGMA poll with 262 responses.[26]
  • 43% of global healthcare providers used third-party providers for payroll services in 2024, based on a survey of 28 healthcare-provider executives.[39]
  • 29% of global healthcare providers used third-party providers for remote patient monitoring in 2024, based on a survey of 28 healthcare-provider executives.[39]
  • 46% of global healthcare providers used third-party providers for customer-experience services in 2024, based on a survey of 28 healthcare-provider executives.[39]
  • 54% of global healthcare providers used third-party providers for supply-chain services in 2024, based on a survey of 28 healthcare-provider executives.[39]

11 Statistics

Finance & Pricing

Pricing remains a major cost signal: a U.S. IVF cycle commonly costs $15,000–$30,000, and a 2026 actuarial analysis estimated average total IVF costs of $29,585 per patient among commercially insured members.

Pricing strategy in the fertility industry

  • $15,000 to $25,000 was the reported U.S. price range for a full IVF cycle in 2024.[40]
  • $5,000 was the median published price for frozen embryo transfer among 110 U.S. clinics surveyed in October 2026.[41]
  • $8,731 was the median published price for egg freezing among 82 U.S. clinics surveyed in October 2026.[41]
  • $1,750 was the median published price for IUI among 71 U.S. clinics surveyed in October 2026.[41]
  • $1,750 was the median published IUI price in the U.S. clinic sample used by The Fertility Index.[41]

Cost reduction in the fertility industry

  • $306 was the modeled labor cost of IVF and embryo freezing at a center performing 2,000 retrieval cycles annually.[42]
  • $7,850 was the modeled activity-based cost of egg freezing in the study’s cost scenario.[42]
  • $578 was the modeled direct cost of IVF and embryo freezing at a center performing 2,000 retrieval cycles annually.[42]
  • 30% was the estimated increase in complex IVF procedure cost when egg count per patient doubled.[42]
  • 55% was the estimated increase in egg-freezing cost when eggs per patient tripled in an IVF activity-based costing study.[42]

Profitability in the fertility industry

  • $3.2 million was INVO Fertility’s adjusted EBITDA loss in fiscal 2025.[11]
  • 555 fertility and family-building clients were served by Progyny at December 31, 2025.[16]
  • $6.450 million was INVO Fertility’s clinic-services revenue in fiscal 2024.[11]
  • $3.718 million was INVO Fertility’s cost of revenue in fiscal 2024.[11]
  • $6.721 million was INVO Fertility’s consolidated clinic revenue in fiscal 2025.[11]

Financial planning in the fertility industry

  • $15,000 was the reported median total cost across women seeking infertility treatment in the cited U.S. cost study.[40]
  • $1,600 was the reported average U.S. cost of preliminary diagnostic fertility testing in 2024.[40]
  • 12% of reproductive-age women reported needing but not receiving fertility services in the 2024 KFF Women’s Health Survey.[40]
  • 27% of U.S. large employers offered IVF coverage in 2024, according to the KFF survey cited by federal regulators.[40]
  • $40,000 to $60,000 was the cited cumulative U.S. IVF cost estimate because patients commonly undergo multiple cycles.[43]

12 Statistics

Product & Service

Services span diagnosis, treatment and preservation, while device and lab automation keeps widening; 3 new medical-device registration certificates were obtained by Basecare in 2024.

Product development in the fertility industry

  • 1 in 6 people globally is estimated to experience infertility, supporting continuing development of fertility diagnostics, laboratory products and treatment services.[44]
  • Mid-single-digit annual growth was reported for the global fertility market served by CooperSurgical’s IVF products and services in 2026.[44]
  • 1 fertility-industry merger created Nexpring Health in 2025 from Hamilton Thorne, Cook Medical’s reproductive-health business and FUJIFILM Irvine Scientific’s medical-media division.[33]
  • 3 new medical-device registration certificates were obtained by Basecare in 2024 for cryopreservation systems, a high-throughput gene sequencer and a sperm-quality analyzer.[12]
  • 80 IVF-device and equipment companies were counted by Inside Reproductive Health in 2026, covering devices and consumables sold to fertility laboratories and clinics worldwide.[33]

Product lifecycle in the fertility industry

  • 53,000 UK patients underwent IVF at licensed fertility clinics in 2024, according to the HFEA’s latest treatment statistics.[15]
  • 1 in 5 UK IVF births in 2024 involved donor eggs, sperm or embryos, according to the HFEA.[15]
  • 6.7 million members were covered by Progyny’s fertility-benefits platform at December 31, 2025, up from approximately 110,000 members when the fertility solution launched in 2016.[11]
  • 2022–2024 treatment, pregnancy and birth data are available for UK licensed fertility clinics through the HFEA’s clinic-level reporting system.[15]
  • 81% of IVF births in the UK in 2024 resulted from treatment using patients’ own eggs and partner sperm.[15]

After-sales in the fertility industry

  • 93% of UK fertility patients providing HFEA feedback in 2024/25 said they understood everything happening throughout their treatment.[15]
  • 73% of UK fertility patients were satisfied with their most recent treatment in the HFEA’s 2024 national survey.[15]
  • 62% of UK private fertility patients in the 2024 HFEA survey received a personalized cost breakdown for treatment.[15]
  • 40% of UK private patients who received a personalized cost breakdown in the 2024 HFEA survey paid more than originally presented.[15]
  • 95% of UK fertility patients providing HFEA feedback in 2024/25 reported being treated with privacy and dignity by clinic staff.[15]

Value proposition in the fertility industry

  • 62% of UK fertility patients identified clinic location as an important factor when choosing a clinic in the HFEA’s 2024 survey.[15]
  • 51% of UK fertility patients identified success rates as an important factor when choosing a clinic in the HFEA’s 2024 survey.[15]
  • 66% of Asian UK fertility patients reported satisfaction with the quality of information received in the 2024 HFEA survey.[15]
  • 47% of Black UK fertility patients identified cost as an important clinic-selection factor in the 2024 HFEA survey.[15]
  • 57% of Black UK fertility patients reported satisfaction with clinic availability to answer questions in the 2024 HFEA survey.[15]

13 Statistics

Sustainability & Ethics

Waste reduction is measurable in clinical operations; an 11% waste reduction for intrauterine insemination and 22% for IVF were estimated in a Netherlands fertility-treatment study.

Sustainability in the fertility industry

  • 8% reduction in material waste was achieved for embryo transfer after sustainability interventions in a medically assisted reproduction program.[42]
  • 234 oocyte retrievals were assessed during a 12-month fertility-care sustainability initiative conducted from October 2023 to October 2024.[42]
  • 11% waste reduction for intrauterine insemination and 22% for IVF were estimated in a Netherlands fertility-treatment study.[30]
  • 400% increase in recycling and more than 30% reduction in clinical waste were achieved after improved waste segregation at a fertility clinic, according to a case study.[45]
  • 50% was the clinical-waste reduction target set by Therapie Fertility Clinic as part of its IVF-laboratory sustainability program.[45]

Ethics in the fertility industry

  • 96% of 108 reporting countries permitted assisted hatching in 2024, according to the IFFS global ART survey.[46]
  • 77% of 57 reporting countries regulated intracytoplasmic sperm injection in 2024, primarily through federal laws.[46]
  • 62% of 105 reporting countries commonly used trophectoderm biopsy in 2024, according to the IFFS global ART survey.[46]
  • 61% of 106 reporting countries permitted polar-body biopsy in 2024, while only 5% reported common use.[46]
  • 25% of 100 reporting countries commonly used blastomere biopsy in 2024, according to the IFFS global ART survey.[46]

Circular economy in the fertility industry

  • More than 30% reduction in clinical waste was reported after correct waste segregation at a fertility clinic participating in an IVF-laboratory sustainability case study.[45]
  • 11% waste reduction was estimated for intrauterine insemination after analyzing material use in fertility treatments in the Netherlands.[30]
  • 22% waste reduction was estimated for IVF after analyzing material use in fertility treatments in the Netherlands.[30]
  • 60% reduction in material waste was achieved for oocyte retrieval through targeted interventions in a medically assisted reproduction program.[42]
  • 400% increase in recycling was reported after correct waste segregation at a fertility clinic participating in an IVF-laboratory sustainability case study.[45]

15 Statistics

Globalization & Expansion

Cross-border demand is documented through multi-country clinic networks and treatment cycles; Europe reported 1.15M+ European ART cycles in 2023.

Globalization in the fertility industry

  • 36 Canadian clinics reported 30,313 patients and 21,697 retrievals in 2024.[54]
  • United States ART cycles more than doubled during the decade ending in 2021.[55]
  • Over 100,000 treatment and freezing cycles were recorded at United Kingdom HFEA-licensed clinics in 2024.[15]
  • Clinics in Kuala Lumpur, Johor Bahru, Singapore and Bali supported Monash IVF Group’s Southeast Asian expansion in 2025.[56]
  • 75 clinics and 28 laboratories operated across nine countries by IVI-RMA Global in 2022.[22]

Cultural adaptation in the fertility industry

  • Median time from first fertility appointment to treatment was 341 days for non-English-speaking patients versus 234.5 days for English-speaking patients.[57]
  • 112 of 916 fertility-treatment patients in an Australian cohort primarily spoke a language other than English.[57]
  • Patients speaking a language other than English received an average of 1.29 IVF cycles versus 1.63 for English-speaking patients.[57]
  • The IVF cancellation rate was 41.33% for non-English-speaking patients versus 28.33% for English-speaking patients in the Australian study.[57]
  • Female same-sex couples in the United Kingdom began fertility treatment at an average age of 32.7 years during 2017–2021.[15]

Stakeholder management in the fertility industry

  • Progyny recorded 65,006 ART cycles for members during 2025.[16]
  • Progyny’s all-member ART utilization rate was 1.32% in 2025.[16]
  • Progyny served 555 employer clients representing 6.689 million members at December 31, 2025.[16]
  • Progyny reported a Progyny Rx Net Promoter Score of +79 at December 31, 2025.[16]
  • Approximately 2,500 patients provided feedback on United Kingdom fertility clinics through HFEA’s Choose a Fertility Clinic webpage in 2024/25.[15]

Distribution channels in the fertility industry

  • Progyny served 555 employer clients representing 6.689 million members through an employer-benefits channel in 2025.[16]
  • HFEA reported that fertility patients may use mobile apps, concierge services and independent healthcare hubs before referral to licensed clinics in 2024/25.[15]
  • INVO Fertility distributed INVOcell technology to third-party fertility clinics while operating four United States fertility clinics in 2026.[11]
  • Progyny had 153 clients with up to 2,500 members in 2025.[16]
  • Progyny had 6.7 million covered members at December 31, 2025, compared with approximately 110,000 in 2016.[16]

Key questions about the Fertility Industry

What is the current global market size for fertility services?
The global fertility-services market was valued at $42.2 billion in 2023 and projected to reach $52.7 billion in 2026.
How fast is the fertility market expected to grow?
The global market is forecast to grow at a 7.5% compound annual growth rate from 2024 through 2030, reaching $70.3 billion by 2030.
Which companies lead the fertility industry?
Ferring Pharmaceuticals leads Gitnux's 2026 fertility ranking with an Overall score of 9.2, with assisted-reproduction technology medicines in assisted reproduction pharmaceuticals. FutureLife is the highest-ranked fertility clinic operator at 9.1, with 61 clinics spanning 15 European countries in fertility clinics and reproductive genetics.
What technology shifts are changing fertility operations?
In 2024, 74.9% of surveyed fertility clinics reported using AI or digital technology in embryology laboratories, while 48.3% cited integration with existing systems as an AI-adoption challenge.
How is the fertility market structured across participants?
The market remains fragmented across fertility clinics, laboratory networks, donor and cryobank providers, pharmaceutical companies and fertility-benefits administrators.
What are typical fertility treatment costs in the United States?
A U.S. IVF cycle commonly costs $15,000–$30,000 when clinic procedures, medications and embryo genetic testing are included; a 2026 actuarial analysis estimated average total IVF costs of $29,585 per patient among commercially insured members in fully mandated states.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Henrik Dahl. (2026, February 13). Fertility Industry Statistics. Gitnux. https://gitnux.org/fertility-industry-statistics
MLA
Henrik Dahl. "Fertility Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/fertility-industry-statistics.
Chicago
Henrik Dahl. 2026. "Fertility Industry Statistics." Gitnux. https://gitnux.org/fertility-industry-statistics.

Sources & references

74 sources cited across this report

  1. europeanfertilitysociety.com
  2. unsw.edu.au
  3. pmc.ncbi.nlm.nih.gov
  4. link.springer.com
  5. healthit.gov
  6. deloitte.com
  7. kpmg.com
  8. business.adobe.com
  9. go.rackspace.com
  10. cetic.br
  11. sec.gov
  12. hkexnews.hk
  13. carta.healthcare
  14. intersystems.com
  15. hfea.gov.uk
  16. investors.progyny.com
  17. ctacquisitions.com
  18. tennr.com
  19. griffin-jones.squarespace.com
  20. physiciangrowthpartners.com
  21. progyny.com
  22. axios.com
  23. time.com
  24. frontiersin.org
  25. mdpi.com
  26. mgma.com
  27. wfhresearch.com
  28. pressganey.com
  29. journals.sagepub.com
  30. academic.oup.com
  31. fertstert.org
  32. fuelonline.com
  33. fertilitybridge.com
  34. media.sproutsocial.com
  35. pewresearch.org
  36. brand-news.it
  37. cdc.gov
  38. stacks.cdc.gov
  39. tcs.com
  40. govinfo.gov
  41. thefertilityindex.com
  42. doi.org
  43. pubsonline.informs.org
  44. thecoopercompaniesinc.gcs-web.com
  45. rbmojournal.com
  46. journals.lww.com
  47. ache.org
  48. proofpoint.com
  49. ponemonsullivanreport.com
  50. kff.org
  51. england.nhs.uk
  52. sophos.com
  53. hfmmagazine.com
  54. cfas.ca
  55. everycrsreport.com
  56. company-announcements.afr.com
  57. pubmed.ncbi.nlm.nih.gov
  58. grandviewresearch.com
  59. focusonreproduction.eu
  60. goodrx.com
  61. iirrm.org
  62. who.int
  63. gedeonrichter.com
  64. ferring.com
  65. futurelifegroup.com
  66. bankrupt.com
  67. merckgroup.com
  68. coopersurgical.com
  69. carefertility.com
  70. genea.com.au
  71. organon.com
  72. indiraivf.com
  73. eshre.eu
  74. nature.com